Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

gp130 receptor ligands as potential therapeutic targets for obesity
Mark A. Febbraio
Mark A. Febbraio
Published April 2, 2007
Citation Information: J Clin Invest. 2007;117(4):841-849. https://doi.org/10.1172/JCI30453.
View: Text | PDF
Science in Medicine Article has an altmetric score of 9

gp130 receptor ligands as potential therapeutic targets for obesity

  • Text
  • PDF
Abstract

Obesity and its related cluster of pathophysiologic conditions including insulin resistance, glucose intolerance, dyslipidemia, and hypertension are recognized as growing threats to world health. It is now estimated that 10% of the world’s population is overweight or obese. As a result, new therapeutic options for the treatment of obesity are clearly warranted. Recent research has focused on the role that gp130 receptor ligands may play as potential therapeutic targets in obesity. One cytokine in particular, ciliary neurotrophic factor (CNTF), acts both centrally and peripherally and mimics the biologic actions of the appetite control hormone leptin, but unlike leptin, CNTF appears to be effective in obesity and as such may have therapeutic potential. In addition, CNTF suppresses inflammatory signaling cascades associated with lipid accumulation in liver and skeletal muscle. This review examines the potential role of gp130 receptor ligands as part of a therapeutic strategy to treat obesity.

Authors

Mark A. Febbraio

×

Total citations by year

Year: 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 1 4 4 1 3 1 1 2 2 5 6 3 2 7 6 2 1 51
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2010 (7)

Title and authors Publication Year
Arcuate Nucleus Proopiomelanocortin Neurons Mediate the Acute Anorectic Actions of Leukemia Inhibitory Factor via gp130
AJ Grossberg, JM Scarlett, XX Zhu, DD Bowe, AK Batra, TP Braun, DL Marks
Endocrinology 2010
Hypothalamic mechanisms in cachexia
AJ Grossberg, JM Scarlett, DL Marks
Physiology & Behavior 2010
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
ML Isidro, F Cordido
Pharmaceuticals (Basel, Switzerland) 2010
Gp130 cytokines exert differential patterns of crosstalk in adipocytes both in vitro and in vivo
UA White, WC Stewart, JM Stephens
Obesity (Silver Spring, Md.) 2010
Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome
A Nikolajuk, I Kowalska, M Karczewska-Kupczewska, A Adamska, E Otziomek, S Wolczynski, I Kinalska, M Gorska, M Straczkowski
Diabetes 2010
IL-17 IN OBESITY AND ADIPOGENESIS
M Ahmed, SL Gaffen
Cytokine & Growth Factor Reviews 2010
PLASMA SOLUBLE SGP130 LEVELS ARE INCREASED IN OLDER SUBJECTS WITH METABOLIC SYNDROME. THE ROLE OF INSULIN RESISTANCE
G Zuliani, M Galvani, M Maggio, S Volpato, S Bandinelli, AM Corsi, F Lauretani, A Cherubini, JM Guralnik, R Fellin, L Ferrucci
Atherosclerosis 2010

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
82 readers on Mendeley
See more details